BC
BHVN

Bridgefront Capital’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Bridgefront Capital’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,634
Closed -$238K – 502
2022
Q2 		$238K Buy
+1,634
New +$209K 0.26% 184
2021
Q3 		– Sell
-3,936
Closed -$382K – 760
2021
Q2 		$382K Buy
+3,936
New +$319K 0.14% 260
2021
Q1 		– Sell
-10,479
Closed -$898K – 1011
2020
Q4 		$898K Buy
+10,479
New +$888K 0.31% 71

Other funds holding BHVN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SFM
Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bridgefront Capital's BHVN Position: Q3 2022 in Review

Bridgefront Capital sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2022, closing a stake of 1,634 shares — an estimated $238K sold.

Bridgefront Capital first reported a position in BHVN in Q4 2020 and held it in 3 quarters. The position peaked at $898K in Q4 2020. 240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

  • Bridgefront Capital reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2022 after selling out during the quarter.
  • Bridgefront Capital sold 1,634 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2022, an estimated $238K.
  • Bridgefront Capital first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2020 and held it in 3 quarters.
  • Bridgefront Capital's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $898K in Q4 2020.
  • 240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2022.

Based on Bridgefront Capital's 13F filing for Q3 2022, filed 29 Nov 2022.